Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Heather M Fitzgerald, Jason Shepherd, Hollie Bailey, Mia Berry, Jack Wright & Maxine Chen. (2021) Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection. Neuropsychiatric Disease and Treatment 17, pages 3215-3228.
Read now
Read now
Articles from other publishers (21)
John M. Kane, Anna Chen, Sangtaeck Lim, Marko A. Mychaskiw, Marc Tian, Yitong Wang, Mark Suett & Jose M. Rubio. (2023) Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. International Clinical Psychopharmacology 38:4, pages 240-248.
Crossref
Crossref
Rachel M. Black, Tamera D. Hughes, Feiyun Ma, Anthony A. Hudzik, Greene Shepherd, Stefanie Ferreri & Sachiko Ozawa. (2023) Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications. Journal of the American Pharmacists Association 63:3, pages 742-750.e3.
Crossref
Crossref
Ana Aliana Miron, Paula Simina Petric, Andreea Teodorescu, Petru Ifteni, Gabriela Chele & Andreea Silvana Szalontay. (2023) Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study. Brain Sciences 13:2, pages 173.
Crossref
Crossref
Alexander Keenan, Dee Lin, Jason Shepherd, Hollie Bailey, Carmela Benson & Sophie Meakin. (2022) Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey. BMC Psychiatry 22:1.
Crossref
Crossref
Larry Alphs, Pamela Baker, Brianne Brown, Dong-Jing Fu, Ibrahim Turkoz & Keith H. Nuechterlein. (2022) Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Schizophrenia Research 248, pages 58-63.
Crossref
Crossref
Roger W. Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du & Peter J. Weiden. (2020) Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums 27:3, pages 262-267.
Crossref
Crossref
Stephan Reymann, Georgios Schoretsanitis, Stephan T. Egger, Alexey Mohonko, Matthias Kirschner, Stefan Vetter, Philipp Homan, Erich Seifritz & Achim Burrer. (2022) Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland. Journal of Personalized Medicine 12:3, pages 441.
Crossref
Crossref
Lisa Lewis & Jill Rodgers. (2022) Development and Evaluation of a Web-Based Educational Toolkit on the Knowledge, Attitudes, and Practices of Psychiatric Prescribers Regarding Long-Acting Injectable Antipsychotics. Journal of the American Psychiatric Nurses Association 28:2, pages 117-127.
Crossref
Crossref
Leslie Citrome, Emily Belcher, Sylvie Stacy, Mark Suett, Marko Mychaskiw & Gregory D Salinas. (2022) Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. Neuropsychiatric Disease and Treatment Volume 18, pages 111-123.
Crossref
Crossref
Sarah E. Forster, Naomi N. Gancz, Marci L. Gaither, Gretchen L. Haas, Kelly D. Starver & Stuart R. Steinhauer. (2022) Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site. Journal of Psychiatric Practice 28:6, pages 497-504.
Crossref
Crossref
Andrea Aguglia, Laura Fusar-Poli, Andrea Amerio, Valeria Placenti, Carmen Concerto, Giovanni Martinotti, Giuseppe Carrà, Francesco Bartoli, Armando D'Agostino, Gianluca Serafini, Mario Amore, Eugenio Aguglia, Giovanni Ostuzzi & Corrado Barbui. (2021) The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. Frontiers in Psychiatry 12.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Daniel Guinart, Heidi Taipale, Jose M Rubio, Antti Tanskanen, Christoph U Correll, Jari Tiihonen & John M Kane. (2021) Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin 47:6, pages 1621-1630.
Crossref
Crossref
Daniel Guinart, Fuminari Misawa, Jose M. Rubio, Justin Pereira, Renato Filippis, Chiara Gastaldon, John M. Kane & Christoph U. Correll. (2021) A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 144:4, pages 329-341.
Crossref
Crossref
Lorenzo Tatini, Giulio D’Anna, Francesco Pietrini, Eugenia Calligaris, Andrea Ballerini & Valdo Ricca. (2021) Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. International Clinical Psychopharmacology 36:4, pages 181-187.
Crossref
Crossref
Andrea Fiorillo, Stefano Barlati, Antonello Bellomo, Giulio Corrivetti, Giuseppe Nicolò, Gaia Sampogna, Valentina Stanga, Franco Veltro, Giuseppe Maina & Antonio Vita. (2020) The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Annals of General Psychiatry 19:1.
Crossref
Crossref
Jean-Pierre Lindenmayer, Ira D. Glick, Hiteshkumar Talreja & Michael Underriner. (2020) Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology 40:4, pages 346-349.
Crossref
Crossref
Amal Abdel‐Baki, Dominic Thibault, Sofia Medrano, Emmanuel Stip, Martin Ladouceur, Ramzan Tahir & Stephane Potvin. (2019) Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder. Early Intervention in Psychiatry 14:1, pages 69-79.
Crossref
Crossref
Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller & Paul Bergmans. (2020) Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Therapeutic Advances in Psychopharmacology 10, pages 204512532098150.
Crossref
Crossref
Luisa Peters, Amanda Krogmann, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. Current Psychiatry Reports 21:12.
Crossref
Crossref
Sandeep Grover, Swapnajeet Sahoo & Aseem Mehra. (2019) Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology 39:6, pages 611-619.
Crossref
Crossref